Cancer Care Centers of Brevard First Site in the World to Open New International Lung Cancer Clinical Trial

Cancer Care Centers of Brevard (CCCB), in collaboration with Sarah Cannon Research Institute (SCRI), has become the first site worldwide to activate and open enrollment for a new international Phase III clinical trial evaluating an investigational treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC), the most common type of lung cancer.

The study is evaluating a novel bispecific therapy designed to target cancer in a new way by helping the immune system better recognize and attack cancer cells. Researchers will compare the investigational treatment with current standard treatment approaches to determine whether it can provide greater clinical benefit for patients whose cancer is driven by specific EGFR mutations.

"Being the first global site to open this study demonstrates our longstanding commitment to bringing innovative research opportunities to patients in our community," said Pavan Kancharla, MD, medical oncologist and hematologist at CCCB. "Clinical trials play a critical role in advancing cancer care, and we're proud to provide access to promising new therapies close to home."

Non-small cell lung cancer accounts for approximately 85% of all lung cancer diagnoses. A subset of patients has tumors driven by EGFR mutations, genetic changes that can fuel cancer growth. While targeted therapies have improved treatment efficacy for many patients, researchers continue to explore new approaches that may help treatments work longer and provide additional benefits over time. This study is part of that ongoing effort.

As the first site globally to activate the study, CCCB is helping lead a worldwide research effort that could contribute to the future standard of care for patients with EGFR-mutated lung cancer. The study's primary objectives include evaluating progression-free survival, overall survival, safety, and tolerability of the investigational treatment compared with current treatment options.

Through its collaboration with SCRI, CCCB provides local patients access to a broad portfolio of clinical trials across multiple cancer types and leverages SCRI’s Accelero model to bring research opportunities to patients quickly. Participation in clinical research allows eligible patients to access investigational therapies while contributing to discoveries that may benefit future generations of cancer patients.

"This milestone demonstrates the strength of our research program and the commitment of our physicians, research staff, and community partners," said Dr. Kancharla. "Our goal is to ensure patients in Brevard County have access to leading-edge cancer care without needing to travel far from home."

Learn more about clinical trials offered locally at Cancer Care Centers of Brevard, or speak with your CCCB provider.

About Cancer Care Centers of Brevard

Cancer Care Centers of Brevard is a comprehensive oncology practice providing medical oncology, hematology, radiation oncology, diagnostic imaging, and clinical research services throughout Brevard County. Through its collaboration with Sarah Cannon Research Institute, CCCB offers patients access to innovative clinical trials and emerging cancer therapies.

Categories: Lung Cancer, Clinical Trials